

***Eurazeo, Merieux Equity Partners, Ardian and Eximium
enter into exclusive discussions with SK Capital
to sell their stake in Seqens***

Lyon, France, August 26, 2021 – Five years after their entry into the capital of Seqens, Eurazeo (majority shareholder), Merieux Equity Partners through its vehicle Mérieux Participations 2 (“MP2”), Ardian and Eximium today announced that they have entered into exclusive discussions to sell their stake in Seqens to funds advised by SK Capital Partners.

Mérieux Equity Partners, Ardian, and Eximium will reinvest part of their proceeds in the transaction. Nov Santé Actions Non Cotées, the fund launched at the initiative of the French Insurance Federation (FFA) and Caisse des Dépôts under their sustainable recovery investment program for France (“Assureurs – Caisse des Dépôts Relance Durable France”) and managed by Eurazeo, will also invest in Seqens. Finally, Bpifrance is currently exploring the possibility of co-investing with SK Capital.

The deal is expected to close by the end of 2021, subject to the fulfillment of the standard conditions precedent for this type of transaction. Through the sale of its stake in Seqens, Merieux Equity Partners would make a 1.8x return on its initial investment, with potential earnouts that could result in a multiple of 2.0x, depending on the company’s future performance.

Since its acquisition in June 2016, with guidance from Eurazeo and supported by Merieux Equity Partners and the other co-investors, Seqens has developed and cemented its status as an integrated global player in pharmaceutical solutions and specialty ingredients, generating €1 billion in annual revenue, with 19 manufacturing sites, seven R&D centers, and nearly 3,000 employees on three continents. During this period, Seqens has also expanded its technological and industrial footprint, investing more than €400 million across all its manufacturing sites and completing three major acquisitions: PCAS in France, Finland and Canada; Chemoxy in the United Kingdom; and PCI Synthesis in the United States.

Thierry Chignon, Managing Partner at Merieux Equity Partners, added: *“We are pleased to have supported Seqens on key topics such as international regulatory issues and strategic choices, target and geographies, for acquisition in order to accelerate its strategic shift to become a global player in the field of small molecules. We would like to thank Eurazeo and Ardian for an open, intense and fruitful collaboration. We were also convinced by the quality of Seqens’ team, and we are delighted to continue this adventure alongside the new reference shareholder, SK Capital”.*

About Merieux Equity Partners - www.merieux-partners.com

Merieux Equity Partners (“MxEP”) is an investment company dedicated to healthcare and nutrition. MxEP actively supports entrepreneurs and companies with differentiated products and services, giving them privileged access to its sector expertise and international network. MxEP currently manages more than €1 billion in assets under management and has launched its latest vehicle MP4 in May 2021, with a target size of €500 million, dedicated to Growth Capital/LBO investments.

Press Contact – Merieux Equity Partners S.A.S.

Thierry CHIGNON, Managing Partner - thierry.chignon@merieux-partners.com / Tel: +33 (0)6 71 30 71 74